BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 30545921)

  • 1. Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG.
    Burke MJ; Salzer WL; Devidas M; Dai Y; Gore L; Hilden JM; Larsen E; Rabin KR; Zweidler-McKay PA; Borowitz MJ; Wood B; Heerema NA; Carroll AJ; Winick N; Carroll WL; Raetz EA; Loh ML; Hunger SP
    Haematologica; 2019 May; 104(5):986-992. PubMed ID: 30545921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131.
    Salzer WL; Burke MJ; Devidas M; Chen S; Gore L; Larsen EC; Borowitz M; Wood B; Heerema NA; Carroll AJ; Hilden JM; Loh ML; Raetz EA; Winick NJ; Carroll WL; Hunger SP
    Cancer; 2018 Mar; 124(6):1150-1159. PubMed ID: 29266189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group.
    Crist W; Shuster J; Look T; Borowitz M; Behm F; Bowman P; Frankel L; Pullen J; Krance R; Steuber P
    Leukemia; 1992; 6 Suppl 2():162-6. PubMed ID: 1578922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
    J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Results of the Risk-adapted Treatment for Childhood B-Cell Acute Lymphoblastic Leukemia: Report From the Japan Association of Childhood Leukemia Study ALL-97 Trial.
    Horibe K; Yumura-Yagi K; Kudoh T; Nishimura S; Oda M; Yoshida M; Komada Y; Hara J; Tawa A; Usami I; Tanizawa A; Kato K; Kobayashi R; Matsuo K; Hori H;
    J Pediatr Hematol Oncol; 2017 Mar; 39(2):81-89. PubMed ID: 28169879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131.
    Salzer WL; Burke MJ; Devidas M; Dai Y; Hardy KK; Kairalla JA; Gore L; Hilden JM; Larsen E; Rabin KR; Zweidler-McKay PA; Borowitz MJ; Wood B; Heerema NA; Carroll AJ; Winick N; Carroll WL; Raetz EA; Loh ML; Hunger SP
    J Clin Oncol; 2020 Aug; 38(23):2628-2638. PubMed ID: 32496902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.
    Pieters R; De Lorenzo P; Ancliffe P; Aversa LA; Brethon B; Biondi A; Campbell M; Escherich G; Ferster A; Gardner RA; Kotecha RS; Lausen B; Li CK; Locatelli F; Attarbaschi A; Peters C; Rubnitz JE; Silverman LB; Stary J; Szczepanski T; Vora A; Schrappe M; Valsecchi MG
    J Clin Oncol; 2019 Sep; 37(25):2246-2256. PubMed ID: 31283407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
    Rytting ME; Thomas DA; O'Brien SM; Ravandi-Kashani F; Jabbour EJ; Franklin AR; Kadia TM; Pemmaraju N; Daver NG; Ferrajoli A; Garcia-Manero G; Konopleva MY; Cortes JE; Borthakur G; Garris R; Cardenas-Turanzas M; Schroeder K; Jorgensen JL; Kornblau SM; Kantarjian HM
    Cancer; 2014 Dec; 120(23):3660-8. PubMed ID: 25042398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No impact of high-dose cytarabine and asparaginase as early intensification with intermediate-risk paediatric acute lymphoblastic leukaemia: results of randomized trial TCCSG study L99-15.
    Kato M; Koh K; Manabe A; Saito T; Hasegawa D; Isoyama K; Kinoshita A; Maeda M; Okimoto Y; Kajiwara M; Kaneko T; Sugita K; Kikuchi A; Tsuchida M; Ohara A
    Br J Haematol; 2014 Feb; 164(3):376-83. PubMed ID: 24164537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML
    JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia.
    Bassan R; Rohatiner AZ; Lerede T; Di Bona E; Rambaldi A; Pogliani E; Rossi G; Fabris P; Morandi S; Casula P; Carter M; Lambertenghi-Deliliers G; Lister TA; Barbui T
    Hematol J; 2000; 1(4):226-34. PubMed ID: 11920195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial.
    Lauer SJ; Shuster JJ; Mahoney DH; Winick N; Toledano S; Munoz L; Kiefer G; Pullen JD; Steuber CP; Camitta BM
    Leukemia; 2001 Jul; 15(7):1038-45. PubMed ID: 11455971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
    J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group.
    Reiter A; Schrappe M; Parwaresch R; Henze G; Müller-Weihrich S; Sauter S; Sykora KW; Ludwig WD; Gadner H; Riehm H
    J Clin Oncol; 1995 Feb; 13(2):359-72. PubMed ID: 7844597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A Pediatric Oncology Group Study.
    van Eys J; Berry D; Crist W; Doering E; Fernbach D; Pullen J; Shuster J; Wharam M
    Cancer; 1989 Jan; 63(1):23-9. PubMed ID: 2910421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia.
    Winick N; Shuster JJ; Bowman WP; Borowitz M; Farrow A; Jacaruso D; Buchanan GR; Kamen BA
    J Clin Oncol; 1996 Oct; 14(10):2803-11. PubMed ID: 8874342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia.
    Hann I; Vora A; Richards S; Hill F; Gibson B; Lilleyman J; Kinsey S; Mitchell C; Eden OB
    Leukemia; 2000 Mar; 14(3):356-63. PubMed ID: 10720126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of relapsed precursor-B acute lymphoblastic leukemia with intensive chemotherapy: POG (Pediatric Oncology Group) study 9411 (SIMAL 9).
    Kelly ME; Lu X; Devidas M; Camitta B; Abshire T; Bernstein ML; Billett A; Homans A; Sandler E; Buchanan G
    J Pediatr Hematol Oncol; 2013 Oct; 35(7):509-13. PubMed ID: 23887024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
    Leahey AM; Bunin NJ; Belasco JB; Meek R; Scher C; Lange BJ
    Med Pediatr Oncol; 2000 May; 34(5):313-8. PubMed ID: 10797352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.